Literature DB >> 8387693

Neutrophil-activating peptide (interleukin-8) in colonic mucosa from patients with Crohn's disease.

R S Izzo1, K Witkon, A I Chen, C Hadjiyane, M I Weinstein, C Pellecchia.   

Abstract

We considered the role of two neutrophil chemotactic agents (interleukin-8 and leukotriene B4) and of myeloperoxidase (a neutrophil-associated enzyme) in the pathologic condition of Crohn's disease (CD). Serial biopsy samples were taken at different sites in the colon, washed in 0.02 M phosphate-saline buffer, homogenized, and then sonicated. Interleukin-8 levels were significantly increased throughout the colonic mucosa (> 300 pg/mg protein) in patients with CD compared with control groups (< 40 pg/mg protein) (p < or = 0.01). A two- to six-fold increase in leukotriene B4 was also found in CD, whereas mucosal levels of myeloperoxidase were unchanged compared with control subjects. This study demonstrates that interleukin-8 and leukotriene B4 may have an immunologic role in the pathologic condition of CD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387693     DOI: 10.3109/00365529309090244

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  21 in total

1.  Cyclosporine A inhibits interleukin-8 production in a human colon epithelial cell line (HT-29).

Authors:  O Saitoh; R Matsuse; K Sugi; K Nakagawa; K Uchida; K Maemura; K Kojima; I Hirata; K Katsu
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

2.  Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Osamu Tsuruta; Nobuo Tomiyasu; Kosuke Takaki; Asuka Suzuki; Junya Masuda; Hiroshi Yamasaki; Atsushi Toyonaga; Michio Sata
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

3.  Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation.

Authors:  Lobke Snoeks; Christopher R Weber; Kaarin Wasland; Jerrold R Turner; Charles Vainder; Wentao Qi; Suzana D Savkovic
Journal:  Lab Invest       Date:  2009-07-27       Impact factor: 5.662

4.  Augmented expression of secondary lymphoid tissue chemokine and EBI1 ligand chemokine in Crohn's disease.

Authors:  D Kawashima; N Oshitani; Y Jinno; K Watanabe; S Nakamura; K Higuchi; T Arakawa
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 5.  Chemokines in the inflammatory bowel diseases.

Authors:  R P MacDermott
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

6.  Interleukin-8 production by the human colon epithelial cell line HT-29: modulation by interleukin-13.

Authors:  G Kolios; D A Robertson; N J Jordan; A Minty; D Caput; P Ferrara; J Westwick
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

7.  IFN-gamma synergizes with TNF-alpha but not with viable H. pylori in up-regulating CXC chemokine secretion in gastric epithelial cells.

Authors:  M Kraft; S Riedel; C Maaser; T Kucharzik; A Steinbuechel; W Domschke; N Luegering
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

8.  In vitro and in vivo impact of a new glycosphingolipid on neutrophils.

Authors:  E Tubaro; C Croce; G Cavallo; L Belogi; G Guida; C Santiangeli; M G Cifone; A Santoni; F Mainiero
Journal:  Agents Actions       Date:  1994-10

9.  The oxysterol receptor LXRβ protects against DSS- and TNBS-induced colitis in mice.

Authors:  T Jakobsson; L-L Vedin; T Hassan; N Venteclef; D Greco; M D'Amato; E Treuter; J-Å Gustafsson; K R Steffensen
Journal:  Mucosal Immunol       Date:  2014-05-07       Impact factor: 7.313

10.  Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex.

Authors:  Manabu Suzuki; Tadakazu Hisamatsu; Daniel K Podolsky
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.